|Day Low/High||26.33 / 26.79|
|52 Wk Low/High||26.00 / 44.18|
Let's check of the charts and indicators to see if this is a good time to approach the long side of MYL.
And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.
These are just a few of the names I expect to do well to close out 2018.
These are a few of the names I expect to do well to close out 2018.
The erratic CEO and awful fundamentals make it impossible to value TSLA -- despite attractive technicals.
While the move higher for crude prices late Tuesday took the energy sector with it, defense and aerospace names saw benefit as well.
Subscriber Comment of the Day (Part Deux): Neil S Allergan's stock is probably seeing additional weakness from two announcements: Mylan's biosmilar Botox partnership with Revance and the Food and Drug Administration's extension of the PDUFA date for...
Gains are being left on the table as firms and investors let their politics or social concerns get the better of them.
I'm seeing some weakness in generic-drug stocks -- i.e., Teva Pharmaceuticals , Mylan and Mallinckrodt -- based on a New York Times article that hospitals might move into the generic-drug business.
I missed very little and was better served at my "liquid" lunch meeting. Bitcoin was being bitcoin (+17%) with prices contrasting wildly by Exchanges -- a signpost that volatility will be with this commodity for some time. I have a double dose of Bo...
Some mid afternoon observations: * Small yield flattening in today's session and little change in bond yields. * High yield is slipping a bit. * The U.S. Dollar is strengthening after morning weakness. * Oil down after weeks of strength (-$0.76/ba...
The Nasdaq (QQQs) turn slightly negative as most of the FANGs reverse lower. Retail, generics (Teva and Mylan ), big pharma (Merck and Bristol-Myers Squibb ) and biotech (Allergan , Gilead Sciences , Celgene ) are conspicuous to the downside. Co...
The Saudi Arabian economy needs to rebalance away from oil.
The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.
Yesterday I reemphasized that Teva should be avoided. Today Mylan was hit by an apparent extension of a generic drug pricing collusion probe. Mylan's shares have fallen by nearly seven precnet in the morning session.
On Wednesday I explained why I would avoid Teva Pharmaceutical Industries : I know by the Comments Section that there has been a lot of bottom fishing in Teva (TEVA) . I had done a few hours of research on the company over the last months and passed...
The three major indexes closed at record highs, the Dow for its third day in a row, the Nasdaq its fourth, and the S&P 500 its fifth.
Risk is harder to gauge than a price target after a gap like the one we have on MYL.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks.
Mylan scored FDA approval for a generic version of Teva Pharmaceuticals' multiple sclerosis drug, Copaxone.
The Israeli pharma company Teva has established a rich history since its founding in 1901. Can it continue to survive as it faces one challenge after another?
The pharmaceutical company on Oct. 3 said the FDA has approved its generic version of Teva's multiple sclerosis drug Copaxone.
Mylan's drug approval announced this morning is a big negative for Teva Pharmaceutical Industries and likely will result in a $3 to $5 drop in Allergan's shares in the early going.